Group 1 - Health care stocks have outperformed the S&P 500 over the past three months, with an average gain of 11.55%, but Pfizer's shares have declined by 5% since the start of October [3][8] - Other major pharmaceutical companies like Johnson & Johnson, Regeneron Pharmaceuticals, and Eli Lilly have seen significant gains of nearly 14%, 24%, and 25% respectively during the same period [4] - Pfizer's recent acquisition of obesity biotech Metsera for $10 billion has only resulted in a modest 0.23% gain in its stock since the announcement [4] Group 2 - Pfizer is aiming to expand its presence in the weight loss drug market to recover revenue lost from declining demand for mRNA-based COVID-19 vaccines [5][8] - The company has entered into a $2.1 billion licensing agreement with China's YaoPharma to develop a GLP-1 weight loss pill, which is in early-stage development [5][8] - The agreement includes an upfront payment of $150 million to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, and potential milestone payments of up to $1.94 billion based on the drug's approval progress [6][7]